Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Silence Therapeutics and InteRNA Technologies have agreed to combine the delivery capabilities of Silence's proprietary AtuPLEX delivery system with InteRNA's novel microRNAs to develop novel microRNA therapeutics for the treatment of cancer.
Subscribe to our email newsletter
Silence is currently conducting a Phase I trial with Atu027 in patients with advanced solid cancer.
Interim data analysis from this trial showed that Atu027 is safe and well tolerated and provided broad support for AtuPLEX as an effective siRNA delivery technology with the potential to overcome the delivery challenges currently associated with RNAi therapeutics.
InteRNA and Silence will undertake in vitro and in vivo studies of the candidate drugs developed under the agreement and select lead candidates for further evaluation.
Silence is eligible to receive upfront fees as well as staged research payments.
Silence Therapeutics COO Thomas Christély said it is in their interest to broaden the potential value of AtuPLEX delivery system as a vehicle to modify gene expression using different oligonucleotide classes, alongside our continuing focus on internal siRNA therapies.